Misonix Incorporated To Showcase Ultrasonic BoneScalpel™ At The International Meeting On Advanced Spine Techniques

FARMINGDALE, N.Y., July 16, 2014 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, announced today that it is exhibiting at the 21^st International Meeting on Advanced Spine Technologies (IMAST) in Valencia, Spain, from July 16-18, 2014 and that it will host a hands-on workshop on ultrasonic bone surgery on July 17 that will be moderated and presented by leading surgeon experts.

The IMAST meeting is an international forum to gather leading spine surgeons for three days to discuss, debate, and demonstrate innovative research and the most advanced spine technologies to help improve patient care. Course highlights include latest research on new and advanced techniques in treating scoliosis, trauma, tumors, and degenerative diseases. The meeting is organized by the Scoliosis Research Society, comprising of more than 1,000 of the world’s leading spine surgeons, researchers, physician assistants and orthotists who are involved in research and treatment of predominantly spinal deformities. Last year’s international meeting was attended by 550 delegates, the majority of attendees are historically from the U.S.

Misonix will showcase its ultrasonic BoneScalpel, which is rapidly being adopted by leading spine and spinal deformity surgeons around the globe. Its ultrasonic technology allows for unique benefits over traditional bone cutting tools as it encourages bone dissection in larger segments while sparing elastic soft tissue structures such as important nerves and arteries. Therapeutic ultrasound is well known for its coagulative effects and the BoneScalpel has been reported to substantially reduce blood loss, use of cell saving blood transfusions and operative time in spinal osteotomies and multilevel decompressions.

Dr. Peter Newton from Rady Children’s Hospital in San Diego, CA will moderate a hands-on workshop reviewing the clinical experience at four leading institutions in the U.S. and Europe. Among the experiences presented will be benefits over traditional technologies, clinical experience as well as new techniques and tips for improving correction of life altering deformities in pediatric and adult patients. The presenting faculty includes moderator Dr. Peter Newton, Dr. Suken Shah from Nemours/Alfred I. DuPont Children’s Hospital, Wilmington, DE, Dr. Amer Samdani from Shriners Hospitals for Children, Philadelphia, PA and Dr. Sean Molloy from Royal National Orthopaedic Hospital, Stanmore, UK. Attending surgeons will have the opportunity to use the BoneScalpel on bone and soft tissue models and engage in detailed discussions with the faculty.

Dr. Peter Newton elaborated on his personal experience, “The ultrasonic BoneScalpel has been an important addition to my surgical tool set. We recently published our study findings that showed a reduction in blood loss using BoneScalpel for deformity surgery in adolescent idiopathic scoliosis and the changes in surgical technique possible when utilizing BoneScalpel.”

Dr. Suken Shah, commented in kind, “BoneScalpel adds an element of safety and convenience to my surgery that allows my residents to advance faster into performing various techniques for bone cutting.”

Dr. Amer Samdani concurred by saying, “We adopted this new technology very quickly at our institution due to its precision and safety compared to traditional methods.”

Dr. Sean Molloy concluded “I have used BoneScalpel for several years now in a wide range of spinal decompressions, fusions and tumor surgeries. It has allowed me to perform my surgeries very efficiently with reduced blood loss and time savings.”

Michael A. McManus, Jr., President and Chief Executive Officer of Misonix comments, “We are extremely pleased by the expanding evidence on BoneScalpel’s unique benefits and its increasing utilization in advanced spine surgeries around the world. The International Meeting on Advanced Spine Technologies is one of the most renowned spine meetings and thus an important podium to showcase the BoneScalpel that is being seen by numerous leading surgeons as one of the most important innovations to spine surgery in the last decade. We are very excited about the opportunity to host a hands-on workshop on use of the BoneScalpel with a high caliber team of surgeon experts. Doctors from Asia, Europe and the Middle East are already signed up for this workshop. We continue to be excited about the building acceptance of the BoneScalpel as a device that is recognized to be safer, more adept at making fine cuts, resulting in less bone fragmentation, less blood loss and a reduction in the operating time necessary to complete the procedure.”

About Misonix

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

SOURCE Misonix, Inc.